4Seligman VA, Lum RF, Olson JL, et al. Demographic differ- ences in the development of lupus nephritis: a retrospective analysis. Am J Med, 2002,112: 726-729.
5Bematsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum, 2006, 54: 2550-2557.
6Austin HA 3rd, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med, 1986, 14: 614-619.
7ttoussiau FA, Vascoucelos C, D'Cruz D, et al. Immunosuppres- sive therapy in lupus nephritis: the Eum-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cy- elophosphamide. Arthritis Rheum, 2002, 46: 2121-2131.
8Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and mana gement of lupus nephritis. Arthritis Care Res (Hoboken),2012,64: 797-808.
9Boumpas DT, Austin HA 3rd, Vaughan EM, et al. Risk for sustained amenorrhea in patients with systemic lupus erythemato- sus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med, 1993, 119: 366-369.
10Dooley MA, Aranow C, Ginzler EM. Review of ACR renal crite- ria in systemic lupus erythematosus. Lupus, 2004, 13: 857-860.
